MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
UroGen Pharma Ltd. DPO Ratio 2011-2026 | URGN
Annual DPO Ratio UroGen Pharma Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 338 | 358 | 235 | 270 | 321 | 1.18 K | - | 865 | 2.7 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.7 K | 235 | 783 |
Quarterly DPO Ratio UroGen Pharma Ltd.
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 332 | 315 | - | 258 | 298 | 337 | - | 168 | 217 | 252 | - | 113 | 165 | 300 | - | 326 | 349 | 476 | - | 966 | 6.22 K | - | - | - | - | - | - | 370 | 1.23 K | 755 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.22 K | 113 | 707 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
64.8 | $ 350.13 | 2.98 % | $ 188 B |  USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Amneal Pharmaceuticals
AMRX
|
21.1 | $ 12.73 | 3.33 % | $ 3.99 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.48 | 8.82 % | $ 394 M |  Britain |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.57 | 5.59 % | $ 3.13 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
186 | $ 2.68 | 4.28 % | $ 16.8 M | USA |
 |
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
Cerus Corporation
CERS
|
242 | $ 1.93 | 4.62 % | $ 368 M | USA |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
CTI BioPharma Corp.
CTIC
|
306 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.2 K | - | - | $ 2.18 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
52.8 | - | - | $ 2.02 B | USA |
 |
Coherus BioSciences
CHRS
|
507 | $ 1.73 | 3.59 % | $ 203 M | USA |